ARTV
Artiva BiotherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case assumes positive late-stage signals, a favorable labeling pathway or buyout interest leading to a significant re-rate; limited near-term dilution and execution on partnerships support valuation expansion.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.4.
What can break
Bear case assumes trial setbacks or need for heavy dilution to fund programs, compressing per-share value; small float and low liquidity can exacerbate selling pressure.
Momentum
88
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.76 · Bull $7.62 · Bear $2.54
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-21 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $35.80
Why
Momentum88 · Δ7d -3.4
Value41 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
+11.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 87.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$485.88M
Beta
-
Shares Out
48.59M
P/E (TTM) · Derived
-2.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.06
Rev YoY
-100.0%
EPS YoY
+14.2%
Gross Margin
-868.5%
Op Margin
-26806.4%
Net Debt
-$97.07M
Current Ratio
8.16
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology